KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Assets Average (2016 - 2025)

Historic Assets Average for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to $641.1 million.

  • Xenon Pharmaceuticals' Assets Average fell 2545.45% to $641.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641.1 million, marking a year-over-year decrease of 2545.45%. This contributed to the annual value of $881.5 million for FY2024, which is 255.93% up from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Assets Average stood at $641.1 million, which was down 2545.45% from $708.8 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Assets Average ranged from a high of $941.9 million in Q1 2024 and a low of $239.9 million during Q1 2021
  • Moreover, its 5-year median value for Assets Average was $708.8 million (2025), whereas its average is $662.7 million.
  • In the last 5 years, Xenon Pharmaceuticals' Assets Average surged by 19369.3% in 2022 and then plummeted by 2545.45% in 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Assets Average (Quarter) stood at $418.2 million in 2021, then soared by 82.93% to $765.0 million in 2022, then grew by 6.92% to $817.9 million in 2023, then dropped by 0.11% to $817.0 million in 2024, then fell by 21.54% to $641.1 million in 2025.
  • Its last three reported values are $641.1 million in Q3 2025, $708.8 million for Q2 2025, and $770.7 million during Q1 2025.